Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis

AntiTNF-α biosimilars are broadly available for the treatment of inflammatory arthritis. There are a lot of data concerning the maintenance of clinical efficacy after switching from originators to biosimilars; therefore, such a transition is increasingly encouraged both in the US and Europe. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Ditto, Maria Chiara, Parisi, Simone, Priora, Marta, Sanna, Silvia, Peroni, Clara Lisa, Laganà, Angela, D’Avolio, Antonio, Fusaro, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527334/
https://www.ncbi.nlm.nih.gov/pubmed/32999362
http://dx.doi.org/10.1038/s41598-020-73183-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527334/
https://www.ncbi.nlm.nih.gov/pubmed/32999362
http://dx.doi.org/10.1038/s41598-020-73183-0

Ejemplares similares